Mahmoud A. Al-Sha`er*, Rua`a A. Al-Aqtash and Mutasem O. Taha Pages 1 - 14 ( 14 )
Background: PI3Kδ is predominantly expressed in hematopoietic cells and participates in the activation of leukocytes. PI3Kδ inhibition is a promising approach for treating inflammatory diseases and leukocyte malignancies. Accordingly, we decided to model PI3Kδ binding.
Methods: Seventeen PI3Kδ crystallographic complexes were used to extract 94 pharmacophore models. QSAR modelling was subsequently used to select the superior pharmacophore(s) that best explain bioactivity variation within a list of 79 diverse inhibitors (i.e., upon combination with other physicochemical descriptors).
Results: The best QSAR model (r2 = 0.71, r2 LOO = 0.70, r2 press against external testing list of 15 compounds = 0.80) included a single crystallographic pharmacophore of optimal explanatory qualities. The resulting pharmacophore and QSAR model were used to screen the National Cancer Institute (NCI) database for new PI3Kδ inhibitors. Two hits showed low micromolar IC50 values.
Conclusion: Crystallography-based pharmacophores were successfully combined with QSAR analysis for the identification of novel PI3Kδ inhibitors.
Co-crystallized structure, PI3Kδ, Anticancer, Pharmacophore modeling, Docking, Roc analysis
Faculty of Pharmacy, Zarqa University, P.O.Box 132222, Zarqa, 13132, Faculty of Pharmacy, Zarqa University, P.O.Box 132222, Zarqa, 13132, Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan, Amman